Medicus Pharma Stock Performance
| MDCX Stock | 3.95 0.25 6.76% |
Medicus Pharma holds a performance score of 5 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 3.29, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Medicus Pharma will likely underperform. Use Medicus Pharma coefficient of variation, jensen alpha, and the relationship between the downside deviation and information ratio , to analyze future returns on Medicus Pharma.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Medicus Pharma are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental indicators, Medicus Pharma showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:2 | Last Split Date 2024-10-25 |
1 | Medicus Pharma readies for IPO as it targets 20B industry - The Business Journals | 11/08/2024 |
2 | MDCX - Medicus Pharma Ltd. Latest Stock News Market Updates - StockTitan | 11/15/2024 |
3 | MDCX Medicus Pharma 3Q 2024 Financial Results Reported Stock Now Trades Both in Canada and on Nasdaq After Completing an IPO in the U.S. - Yahoo Finance | 11/27/2024 |
4 | Medicus Pharma Secures FDA MUMS Status for Novel Cancer Treatment Patch in 200M Equine Market - StockTitan | 12/12/2024 |
| Begin Period Cash Flow | 267.7 K | |
| End Period Cash Flow | 1.7 M | |
| Free Cash Flow | -4.2 M |
Medicus |
Medicus Pharma Relative Risk vs. Return Landscape
If you would invest 434.00 in Medicus Pharma on September 15, 2024 and sell it today you would lose (39.00) from holding Medicus Pharma or give up 8.99% of portfolio value over 90 days. Medicus Pharma is generating 1.0032% of daily returns assuming 15.0473% volatility of returns over the 90 days investment horizon. Simply put, majority of traded equity instruments are less risky than Medicus on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medicus Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medicus Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medicus Pharma, and traders can use it to determine the average amount a Medicus Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0667
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MDCX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.05 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.0 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Medicus Pharma is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medicus Pharma by adding it to a well-diversified portfolio.
Medicus Pharma Fundamentals Growth
Medicus Stock prices reflect investors' perceptions of the future prospects and financial health of Medicus Pharma, and Medicus Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medicus Stock performance.
| Current Valuation | 39.63 M | |||
| Shares Outstanding | 11.82 M | |||
| Price To Book | 9.40 X | |||
| Net Income | (6.78 M) | |||
| Total Debt | 1.09 M | |||
| Cash Flow From Operations | (4.16 M) | |||
| Earnings Per Share | (1.25) X | |||
| Total Asset | 1.89 M | |||
| Retained Earnings | (19.18 M) | |||
About Medicus Pharma Performance
Evaluating Medicus Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Medicus Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medicus Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Medicus Pharma is entity of Canada. It is traded as Stock on V exchange.Things to note about Medicus Pharma performance evaluation
Checking the ongoing alerts about Medicus Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medicus Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medicus Pharma is way too risky over 90 days horizon | |
| Medicus Pharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (6.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Medicus Pharma generates negative cash flow from operations | |
| Latest headline from news.google.com: Medicus Pharma Secures FDA MUMS Status for Novel Cancer Treatment Patch in 200M Equine Market - StockTitan |
- Analyzing Medicus Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medicus Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Medicus Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medicus Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medicus Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medicus Pharma's stock. These opinions can provide insight into Medicus Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medicus Stock Analysis
When running Medicus Pharma's price analysis, check to measure Medicus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicus Pharma is operating at the current time. Most of Medicus Pharma's value examination focuses on studying past and present price action to predict the probability of Medicus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicus Pharma's price. Additionally, you may evaluate how the addition of Medicus Pharma to your portfolios can decrease your overall portfolio volatility.